Radiation recall dermatitis induced by COVID-19 vaccination in breast cancer patients treated with postoperative radiation therapy

Background: and purpose: Radiation recall dermatitis is an adverse event predominantly due to systemic therapy administration after a previous radiation therapy course. Few case reports describe radiation recall dermatitis in breast cancer patients treated with postoperative radiation therapy following COVID-19 vaccination. In this study we investigated the incidence and severity of radiation recall dermatitis after COVID-19 vaccination in irradiated breast cancer patients. Methods: Patients that received at least one COVID-19 vaccination dose during the year after the end of postoperative breast radiation therapy were included in this observational monocentric study. Local symptoms occurring inside the radiation field after vaccination were patient-reported and scored according to the PRO-CTCAE questionnaire. Descriptive data of radiation recall dermatitis incidence and severity, and potential risk factors were evaluated. Results: A cohort of 361 patients with 756 administered COVID-19 vaccinations was analyzed. Breast symptoms were reported by 7.5% of patients, while radiation recall dermatitis was considered for 5.5%. The incidence of radiation recall dermatitis per single dose of vaccine was 2.6%, with a higher risk for the first dose compared to the second/third (4.4% vs 1%, p = 0.003), especially when administered within the first month after the end of irradiation (12.5% vs 2.2%, p = 0.0004). Local symptoms were generally self-limited and a few cases required anti-inflammatory drugs. Conclusions: Radiation recall dermatitis is an uncommon but not rare phenomenon in breast cancer patients that received COVID-19 vaccination within one year after breast irradiation. However, symptoms severity were generally low/mild and reversible. These findings can be useful for patient counseling

Pulsed Direct And Constant Direct Currents In The Pilocarpine Iontophoresis Sweat Chloride Test

Background: The classic sweat test (CST) is the golden standard for cystic fibrosis (CF) diagnosis. Then, our aim was compare the production and volume of sweat, and side effects caused by pulsed direct current (PDC) and constant direct current (CDC). To determine the optimal stimulation time (ST) for the sweat collection. To verify the PDC as CF diagnosis option. Methods: Prospective study with cross-sectional experimental intervention. Experiment 1 (right arm): PDC and CDC. ST at 10 min and sweat collected at 30 min. Currents of 0.5; 0.75; 1.0 and 1.5 mA and frequencies of 0, 200, 1,000 and 5,000 Hz applied. Experiment 2 (left arm): current of 1.0 mA, ST at 5 and 10 min and sweat collected at 15 and 30 min with frequencies of 0; 200; 1,000 and 5,000 Hz applied Experiments 1 and 2 were performed with current density (CD) from 0.07 to 0.21 mA/cm2. Experiment 3: PDC was used in typical CF patients with two CFTR mutations screened and or with CF diagnosis by rectal biopsy and patients with atypical CF. Results: 48 subjects (79.16% female) with average of 29.54 ± 8.87 years old were enrolled. There was no statistical difference between the interaction of frequency and current in the sweat weight (p = 0.7488). Individually, positive association was achieved between weight sweat and stimulation frequency (p = 0.0088); and current (p = 0.0025). The sweat production was higher for 10 min of stimulation (p = 0.0023). The sweat collection was better for 30 min (p = 0.0019). The skin impedance was not influenced by ST and sweat collection (p > 0.05). The current frequency was inversely associated with the skin impedance (p < 0.0001). The skin temperature measured before stimulation was higher than after (p < 0.0001). In Experiment 3 (29 subjects) the PDC showed better kappa index compared to CDC (0.9218 versus 0.5205, respectively). Conclusions: The performance of the CST with CDC and PDC with CD of 0.14 to 0.21 mA/cm2 showed efficacy in steps of stimulation and collection of sweat, without side effects. The optimal stimulation time and sweat collection were, respectively, 10 and 30 min.141Di Sant'S Agnese, P.A., Darling, R.C., Perara, G.A., Shea, E., Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas (1953) Am J Dis Child, 86, pp. 618-619Gibson, L.E., Cooke, R.E., A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis (1959) Pediatrics, 23, pp. 545-549Taylor, C.J., Hardcastle, J., Southern, K.W., Physiological measurements confirming the diagnosis of cystic fibrosis. The sweat test and measurements of transepithelial potential difference (2009) Paedia Resp Rev, 10, pp. 220-226Rosenstein, B.J., What is a cystic fibrosis diagnosis? (1998) Clin Chest Med, 19, pp. 423-441Rowe, S.M., Miller, S., Sorscher, E.J., Cystic fibrosis (2005) N Engl J Med, 352, pp. 1992-2001Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report (2008) J Pediatr, 153, pp. S4-e14Castellani, C., Southern, K.W., Brownlee, K., DankertRoelse, J., Duff, A., Farrell, M., Mehta, A., Elborn, S., European best practice guidelines for cystic fibrosis neonatal screening (2009) J Cystic Fibrosis, 8, pp. 153-173Quinton, P.M., Cystic fibrosis: lesson from the sweat gland (2007) Physiology (Bethesda), 22, pp. 212-225Quinton, P.M., Chloride impermeability in cystic fibrosis (1983) Nature, 301, pp. 421-422Collie, J.T.B., Massie, R.J., Jones, O.A.H., LeGrys, V.A., Greaves, R.F., Sixty-Five Years Since the New York Heat Wave: Advances in Sweat Testing for Cystic Fibrosis (2014) Pediatr Pulmonol, 49, pp. 106-117Legrys, V.A., Sweat testing for the diagnosis of cystic fibrosis. Practical considerations (1996) J Pedia, 129, pp. 892-897Gonçalves, A.C., Marson, F.A.L., Mendonça, R.M.H., Ribeiro, J.D., Ribeiro, A.F., Paschoal, I.A., Levy, C.E., Saliva as a potential tool for cystic fibrosisdiagnosis (2013) Diagn Pathol, 8, p. 46Webster, H.L., A clinical appraisal of cystic fibrosis sweat-testing guidelines (2001) Am Clin Lab, 20, pp. 39-42Hammond, K.B., Nelson, L., Gibson, L.E., Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis (1994) J Pediatr, 124, pp. 255-260Portaria N° 288, 21 de Março de 2013. Diário oficial da união, Brasília, N° 56 - DOU - 22/03/13 - seção 1 , p. 47. , ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe_eletronico/2013/iels.mar.13/Iels55/U_PT-MS-SAS-288_210313.pdf, BrasilNumajiri, S., Sakurai, H., Sugibayashi, K., Morimoto, Y., Omiya, H., Takenaka, H., Akiyama, N., Comparison of depolarizing and direct current systems on iontophoretic enhancement of transport of sodium benzoate through human and hairless rat skin (1993) J Pharm Pharmcol, 45, pp. 610-613Zakzewski, C.A., Amory, D.W., Jasaitis, D.K., Li, J.K.J., Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report (1992) CardiovascularDrugs and Therapy, 6, pp. 589-595Bagniefski, T.M., Burnette, R.R., A comparison of pulsed and continuous current iontophoresis (1990) J Cont Release, 11, pp. 113-122Preat, V., Thysman, S., Trandermaliontophoreric delivery of sulfentanilInt (1993) J Pharmaceut, 96, pp. 189-196(2000) Obesity: Preventing and managing the global epidemic, , Geneva: World Health Organization Technical Support Series, 894, Geneva: World Health OrganizationSousa, M., Servidoni, M.F., Vinagre, A.M., Ramalho, A.S., Bonadia, L.C., Felício, V., Ribeiro, M.A., Amaral, M.D., Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis (2012) Plos One, 7, p. e47708Carlsson, A.M., Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale (1983) Pain, 16, pp. 87-101Rosenstein, B.J., Cutting, G.R., The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel (1998) J Pediatr, 132, pp. 589-595Karezeski, B., Cutting, G., Diagnosis of cystic fibrosis. CFTR-related disease and screening (2006) ProgRespir Res, 34, pp. 69-76Strausbaugh, S.D., Davis, P.B., Cystic fibrosis: a review of epidemiology and pathobiology (2007) Clin Chest Med, 28, pp. 279-288Mackay, R., George, P., Kirk, J., Sweat testing for cystic fibrosis: A review of New Zealand laboratories (2006) J Paedia Child Health, 42, pp. 160-164Cirilli, N., Podan, R., Raia, V., Audit of sweat testing: A first report from Italian cystic fibrosis centres (2008) J Cystic Fibrosis, 7, pp. 415-422Kirk, J.M., Inconsistencies in sweat testing in UK laboratories (2000) Arch Dis Child, 82, pp. 425-427Webster, H.L., Laboratory diagnosis of cystic fibrosis (1983) CRC Crit Rev in Clin LabSci, 18, pp. 313-338http://www.wescor.com/biomedical/cysticfibrosis/macroduct.htmlSabbahi, M.A., Costello, C.T., Ernran, A., A method for reducing skin irritation by iontophoresis (1994) PhysTher, 74, p. S156Su, M.H., Srinivasan, V., Ghanem, A.H., Higuchi, W.I., Quantitative in vivo iontophoreticstudies (1994) J Pharm Sci, 83, pp. 12-17Huang, Y.-Y., Wu, S.-M., Transdermal Iontophoretic Delivery of Thyrotropin-Releasing Hormone Across Excised Rabbit Pinna Skin Drug Dev (1996) Ind Pharm, 22, pp. 1075-1081Knoblauch, P., Moll, F., In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis (1993) J Control Release, 26, pp. 203-212Okabe, K., Yamaguchi, H., Kawai, Y., New iontophoretic transdermal administration of the beta-blocker metoprolol (1986) J Control Release, 4, pp. 79-85Li, S.K., Higuchi, W.I., Zhu, H., Kern, S.E., Miller, D.J., Hastings, M.S., In vitro and in vivo comparisons of constant resistance AC iontophoresis and DC iontophoresis (2003) J Control Release, 91, pp. 327-343Banga, A.K., Chien, Y.W., Iontophoretic delivery of drugs: fundamentals, developments and biomedical application (1988) J Control Rel, 7, p. 1Panzade, P., Heda, A., Puranik, P., Patni, M., Mogal, V., Enhanced Transdermal Delivery of Granisetron by Using Iontophoresis (2012) IJPR, 11, pp. 503-512Chen, L.L.H., Chien, Y.W., Transdermal iontophoretic permeation of luteinizing hormone releasing hormone: characterization of electric parameters (1996) J Control Release, 40, pp. 187-198Chien, Y.W., Siddiqui, O., Shi, W.M., Lelawongs, P., Liu, J.C., Direct current iontophoretic transdermal delivery of peptide and protein drugs (1989) J Pharm Sci, 78, pp. 376-383Hirvonen, J., Hueber, F., Guy, R.H., Current profile regulates iontophoretic delivery of amino acids across the skin (1995) J Control Release, 37, pp. 239-249Kanebako, M., Inagi, T., Takayama, K., Transdermal delivery of iondomethacin by iontophoresis (2002) Biol Pharm Bull, 25, pp. 779-782Abramowitz, D., Neoussikine, B., (1946) Treatment by Ion Transfer, p. 87. , NewYork: Grune and StrattonLeGrys, V.A., Applequist, R., Briscoe, D.R., Farrell, P., Hickstein, R., Lo, S.F., Passarell, R., Vaks, J.E., Sweat testing: sample collection and quantitative chloride analysisapproved guidelines - Third Edition (2009) Clin Lab Stand Ins, 29. , C34-A2Beauchamp, M., Lands, L.C., Sweat-Testing: A Review of Current Technical Requirements (2005) Pediatr Pulmonol, 39, pp. 507-511Chiang, C.H., Shao, C.H., Chen, J.L., Effects of pH electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide (1998) Drug Dev Ind Pharm, 24, pp. 431-438Van der Geest, R., Banhof, M., Bodde, H.E., Iontophoretic delivery of apomorphine I. In-vitro optimization and validation (1997) Pharm Res, 14, pp. 1798-1803Heap, S., Guidelines for the Performance of the Sweat Test for the Investigation of Cystic Fibrosis in the UK 2nd Version. An Evidence Based Guideline (2014) R College Paediatr Child Health, 2, pp. 1-121Kalia, Y.N., Naik, A., Garrison, J., Guy, R.H., Iontophoretic drug delivery (2004) Adv Drug DelivVer, 56, pp. 619-658Barry, B.W., Drug delivery routes in skin: a novel approach (2002) Adv Drug Deliv Rev, 54, pp. S31-S40Pikal, M.J., The role of electroosmotic flow in transdermal iontophoresis (1992) Adv Drug Deliv Rev, 9, pp. 201-237Curdy, C., Kalia, Y.N., Guy, R.H., Post-iontophoresis recovery of human skin impedance in vivo (2002) Eur J Pharm Biopharm, 53, pp. 15-21Ulreich, A., Leibrecht, W., Promer, M., Kullich, W., Infiltration versus iontophoresis in case of epicondylitis. A comparative study. Physikalische Medizin Rehabilitations medizin (1996) Kurortmedizin, 6, pp. 183-185Bolfe, V.J., Ribas, S.I., Montebelo, M.I.L., Guirro, R.R.J., Comportamento da impedância elétrica dos tecidos biológicos durante a estimulação elétrica transcutânea (2007) Rev Bras Fisioter, 11, pp. 153-159Bioelectrical impedance analysis-part I: review of principles and methods (2004) ClinNutr, 23, pp. 1226-1243Nakakura, M., Kato, Y., Hayakawa, E., Kuroda, T., Effect of pulse on iontophoretic delivery of desmopressin acetate in rats (1996) Biol Pharm Bull, 19, pp. 738-740Sagi-Dolev, A.M., Prutchi, D., Nathan, R.H., Three-dimensional current density distribuition under surface stimulation electrodes (1995) Med Biol Eng Comp, 33, pp. 403-408Zhu, F., Scheditz, D., Levin, N.W., Estimation of trunk extracellular volume by bioimpedance (1998) Conf Proc IEEE Eng Med Biol Soc, 20, pp. 3104-3107Chizmadzhev, Y.A., Kuzmin, P.I., Weaver, J.C., Potts, R.O., Skin appendageal macropores as a possible pat way for electrical current (1998) J Investg Dermatol Symp Proc, 3 (2), pp. 148-152Ya-Xian, R.O., Suetake, T., Tagami, H., Number of cell layers of the stratum corneum in normal skin-relationship to the anatomical location on the body, age, sex and physical parameters (1999) Arch Dermatol Res, 291, pp. 555-559Nelson, R.M., Hayes, K.W., Currier, D.P., (1999) Clinical Electrotherapy, pp. 15-54. , 3a. ed. Stanford: Appleton & LangeLow, J., Reed, A., (2000) Electrotherapy Explained: Principles and Practice, , Oxford: Butterworth-HeinemannCameron, M.H., (1999) Physical Agents in Rehabilitation: From Research to Practice, , Philadelphia: W.B.Saunders companyKubisz, L., The influence of storage time on the temperature dependence of the dc electrical conductivity of horn kereatin (2001) Bioelectrochemistry, 53, pp. 161-16

Síndrome de ogilvie em paciente cardiopata: relato de caso / Ogilvie syndrome in heart patient: case report

Em 1948, Heneage Ogilvie descreveu pela primeira vez a Síndrome de Ogilvie, também conhecida como pseudo-obstrução intestinal, que tem como principal característica a distensão do cólon sem causas mecânicas. O presente estudo objetiva relatar um caso de Síndrome de Ogilvie em paciente cardiopata com desfecho trágico. Paciente de 59 anos, sexo feminino, admitida em pronto atendimento com queixa de dispneia e elevações dos níveis pressóricos. Após as medidas iniciais, apresentava pressão arterial em 180x110 mmHg e taquipneia. Foram prescritos nitroglicerina, furosemida, ventilação não invasiva e medidas para a insuficiência cardíaca congestiva. Durante a internação evolui para falência renal com necessidade de hemodiálise. Evoluiu com três paradas cardiorrespiratórias em atividade elétrica sem pulso, devido a hiperpotassemia refratária a medidas clínicas, revertidas.Devido a ausência de evacuação, foram prescritas medidas laxativas. A Tomografia realizada sem contraste evidenciou distensão colônica sem líquido na cavidade ou sinais de obstrução intestinal mecânica. Na colonoscopia havia abundante quantidade de fezes, distensão de reto, cólon sigmoide e descendente. Ao exame físico de abdome notou-se ruídos hidroaéreos diminuídos, distensão, timpanismo à percussão e ausência de dor ou visceromegalias à palpação, levando a hipótese de Sindrome de Ogilvie. Foi prescrita a Neostigmina, porém paciente evoluiu sem melhora e com piora do quadro álgico. Foi realizada uma nova colocoscopia com tentativa de descomprimir o trajeto intestinal, porém devido a ausência de sucesso, foi feita uma transversostomia descompressiva que melhorou o quadro sindrômico, entretanto, paciente evoluiu com hiperpotassemia três dias após o procedimento cirúrgico e nova parada cardiorrespiratória resultando em óbito. A causa exata da Síndrome de Ogilvie permanece desconhecida. A teoria suposta por Ogilvie para explicar a pseudo-obstrução colônica aguda foi um desequilíbrio na atividade do sistema nervoso autônomo, uma supressão da atividade dos nervos parassimpáticos sacrais juntamente com um aumento dos impulsos simpáticos.

Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries

Background: The 2015 Lancet Commission on global surgery identified surgery and anaesthesia as indispensable parts of holistic health-care systems. However, COVID-19 exposed the fragility of planned surgical services around the world, which have also been neglected in pandemic recovery planning. This study aimed to develop and validate a novel index to support local elective surgical system strengthening and address growing backlogs. Methods: First, we performed an international consultation through a four-stage consensus process to develop a multidomain index for hospital-level assessment (surgical preparedness index; SPI). Second, we measured surgical preparedness across a global network of hospitals in high-income countries (HICs), middle-income countries (MICs), and low-income countries (LICs) to explore the distribution of the SPI at national, subnational, and hospital levels. Finally, using COVID-19 as an example of an external system shock, we compared hospitals' SPI to their planned surgical volume ratio (SVR; ie, operations for which the decision for surgery was made before hospital admission), calculated as the ratio of the observed surgical volume over a 1-month assessment period between June 6 and Aug 5, 2021, against the expected surgical volume based on hospital administrative data from the same period in 2019 (ie, a pre-pandemic baseline). A linear mixed-effects regression model was used to determine the effect of increasing SPI score. Findings: In the first phase, from a longlist of 103 candidate indicators, 23 were prioritised as core indicators of elective surgical system preparedness by 69 clinicians (23 [33%] women; 46 [67%] men; 41 from HICs, 22 from MICs, and six from LICs) from 32 countries. The multidomain SPI included 11 indicators on facilities and consumables, two on staffing, two on prioritisation, and eight on systems. Hospitals were scored from 23 (least prepared) to 115 points (most prepared). In the second phase, surgical preparedness was measured in 1632 hospitals by 4714 clinicians from 119 countries. 745 (45·6%) of 1632 hospitals were in MICs or LICs. The mean SPI score was 84·5 (95% CI 84·1–84·9), which varied between HIC (88·5 [89·0–88·0]), MIC (81·8 [82·5–81·1]), and LIC (66·8 [64·9–68·7]) settings. In the third phase, 1217 (74·6%) hospitals did not maintain their expected SVR during the COVID-19 pandemic, of which 625 (51·4%) were from HIC, 538 (44·2%) from MIC, and 54 (4·4%) from LIC settings. In the mixed-effects model, a 10-point increase in SPI corresponded to a 3·6% (95% CI 3·0–4·1; p<0·0001) increase in SVR. This was consistent in HIC (4·8% [4·1–5·5]; p<0·0001), MIC (2·8 [2·0–3·7]; p<0·0001), and LIC (3·8 [1·3–6·7%]; p<0·0001) settings. Interpretation: The SPI contains 23 indicators that are globally applicable, relevant across different system stressors, vary at a subnational level, and are collectable by front-line teams. In the case study of COVID-19, a higher SPI was associated with an increased planned surgical volume ratio independent of country income status, COVID-19 burden, and hospital type. Hospitals should perform annual self-assessment of their surgical preparedness to identify areas that can be improved, create resilience in local surgical systems, and upscale capacity to address elective surgery backlogs. Funding: National Institute for Health Research (NIHR) Global Health Research Unit on Global Surgery, NIHR Academy, Association of Coloproctology of Great Britain and Ireland, Bowel Research UK, British Association of Surgical Oncology, British Gynaecological Cancer Society, and Medtronic

Global wealth disparities drive adherence to COVID-safe pathways in head and neck cancer surgery

Peer reviewe

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.

Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries